Israeli researchers have developed a new vaccine that is “100% effective” Against bacteria It is fatal for humans.
The announcement comes from Tel Aviv University, in collaboration with Israeli biological laboratories, to create the first mRNA-based vaccine to protect bacteria.
“In our research, we show us mRNA vaccine Professor Dan Pier, co-led professor of research, who is the director of Tel Aviv University’s Institute of Precision Nano Medicine, told Fox News Digital.
になったんです。 English: The first thing you can do is to find the best one to do.Arizona residents died of the pneumonia epidemic.
“Yersinia Pestis, the causative agent of plague, is considered a very deadly infectious bacteria that do not have an approved vaccine.”
The bacteria is extremely deadly, even in small quantities, classified by the CDC as a “tier 1 select agent” and, according to peers, is considered a “potential bioterrorist weapon.”
“Several natural local outbreaks have been recorded over the past few years, indicating that Y.Pestis still poses a risk to the population,” he noted.
Researchers have tested novel mRNA vaccines in animals infected with bacteria, a university press release said.
US bubonic plague: Should we worry about catching rodent-borne diseases?
“Within a week, all unvaccinated animals had died, and the animals that were vaccinated with the vaccine remained alive,” the team reported, noting that one dose provided full protection two weeks later.
The findings were published in Science Advances.
Prior to this study, only mRNA vaccines were shown Protects against virusesAccording to Dr. Edcon of Tel Aviv University, co-led research suggests that COVID-19 and others are not bacteria.
“Up to date, scientists believed that mRNA vaccines against bacteria were biologically unattainable,” Kon said in the announcement. “Our research has proven that it is actually possible to develop an mRNA vaccine that is 100% effective against lethal bacteria.”
Viral vaccines cause human cells to produce viral proteins, which can train the immune system and protect against them, but that same method was not effective against bacteria.
Instead, scientists used alternative methods to release bacterial proteins, which created “the important thing.” Immune response. ”
“We buttressed with some of the human proteins to increase the stability of the bacterial proteins and to prevent them from collapse too quickly in the body,” they wrote. “By combining two groundbreaking strategies, we achieved a complete immune response.”
Dr. Jacob Glanville, CEO of San Francisco biotechnology company Centivax, reiterated the importance of this research.
“This is different from coronavirus, flu research cancer“We’ve been driving mRNA vaccine applications so far,” Granville, who wasn’t part of the research team, told Fox News Digital.
The study, he confirmed, demonstrates how mRNA technology can be rapidly applied to “new threat regions.”
“Following the blowback from the obligation and the rare but clearly problematic side effects associated with the first Covid-19 vaccine, mRNA as a platform faced additional scrutiny to ensure that the next generation of vaccines coming out of it learned lessons and improved from the early vaccine,” Granville told Fox News Digital.
“This study illustrates yet another large application area. technology. ”
According to peers, the main limitation of this study is that the vaccine’s effectiveness was demonstrated in mice.
“Like preclinical research, it needs to be evaluated in clinical research to assess its effectiveness in humans,” he told Fox News Digital.
Furthermore, the experimental mRNA vaccine is based on the recently approved “lipid nanoparticle (LNP) mRNA vaccine platform.” COVID-19 VaccinePeers pointed out that peers need “cold chain logistics” (supply chains using refrigerated storage).
“Nevertheless, extensive research has been conducted in our lab, focusing on optimizing the stability of lipid formulations that allow for room temperature storage,” the researchers added.
Researchers say the new technology is to quickly track vaccines for bacterial diseases. This is particularly beneficial for pathogenic (causing disease) and antibiotic-resistant bacteria.
“Over the past decades, due to excessive use of antibiotics, many bacteria have developed resistance to antibiotics and have reduced their effectiveness Important drugs“Pia said.
“As a result, antibiotic-resistant bacteria are already pose a real threat to human health around the world. Developing a new type of vaccine may provide an answer to this global problem.”
Click here to sign up for our health newsletter
As Peer pointed out, rapid development of the Covid-19 vaccine was based on the year mRNA studies For similar viruses.
“If we face a certain bacterial pandemic tomorrow, our research will provide a pathway to rapidly develop safe and effective mRNA vaccines.”
As this was a preclinical proof-of-concept study, peers noted that several major milestones must be met before considering this vaccine for commercial deployment.
However, he believes that in emergencies, the vaccine can be expanded and prepared in a “relatively short period of time.”
Visit us for more health articles www.foxnews.com/health
Peers don’t just deal with the threat of ” The outbreak of plague And in potential bioterrorism, this study opens the door to the development of mRNA vaccines against other antibiotic-resistant bacteria, offering a powerful new strategy to combat increasing antibiotic resistance and improve global pandemic preparation. ”
This study was supported by the European Research Council, the Israeli Institute of Biology, and the Schmunis Family Foundation.
